The Big Orthos continue to grow with their access advantages, new products from M&A, and organized sales force.
The pattern across these orthopedic giants is clear: strong top-line growth from new products, segment momentum in knees/hips, and merger synergies is being rewarded when paired with margin improvements and raised guidance, as seen with Globus (ranked #1 for growth at 18.4%), Alphatec (ranked #2 organic growth at 30%), Stryker (#3 at 9.5% organic), and J&J MedTech (#4 at 6.8%).
However, even solid beats can trigger caution if offset by external factors like tariffs or China pricing pressures (Stryker, Smith & Nephew), or if expectations are sky-high, emphasizing investor scrutiny on execution efficiency and long-term profitability in a competitive MedTech landscape. Lower performers like Orthofix (#9) and Treace (#8) highlight challenges in profitability and modest growth, while Zimmer (#5), Smith & Nephew (#6), Enovis (#7), and Globus set benchmarks for innovation-driven recovery.
Zimmer Biomet ranked moderately in performance among orthopedic peers, delivering solid Q2 2025 results with steady growth but lagging behind high-growth merger-driven compet...
